U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C27H27N5O3
Molecular Weight 469.535
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CP-724714

SMILES

COCC(=O)NC\C=C\C1=CC2=C(C=C1)N=CN=C2NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3

InChI

InChIKey=LLVZBTWPGQVVLW-SNAWJCMRSA-N
InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+

HIDE SMILES / InChI
Molecular Formula C27H27N5O3
Molecular Weight 469.535
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT00055926 | https://clinicaltrials.gov/ct2/show/NCT00102895

CP 724714 is an orally bioavailable, quinazoline-based, selective small molecule inhibitor of the HER2/erbB2 receptor tyrosine kinase. The compound could have particular potential in the treatment of women with metastatic breast cancer, of which 25-30% over express HER2/erbB2. CP 724714 was in preclinical development with Pfizer.

Originator

OSI Pharmaceuticals|Pfizer
4
Curator's Comment: CP 724714 was originated through a collaboration between OSI Pharmaceuticals and Pfizer. # OSI Pharmaceuticals and Pfizer

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 32.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4940 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4900 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3660 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
250 mg 2 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2740 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
250 mg 2 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4940 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17805538
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4900 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17805538
400 mg 2 times / day single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3990 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17805538
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14900 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11900 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9300 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
250 mg 2 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7360 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
250 mg 2 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14900 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17805538
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11900 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17805538
400 mg 2 times / day single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7720 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17805538
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.34 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17317835
250 mg 2 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.34 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17805538
400 mg 2 times / day single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.8 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17805538
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CP-724714 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17805538
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/17805538
Sources:
https://pubmed.ncbi.nlm.nih.gov/17805538
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
DLT: Hyperbilirubinemia, ALT increased...
Dose limiting toxicities:
Hyperbilirubinemia (grade 3, 20%)
ALT increased (grade 3, 20%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
250 mg 2 times / day multiple, oral
RP2D
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
DLT: thrombocytopenia, Pulmonary embolism...
Dose limiting toxicities:
thrombocytopenia (grade 3, 6.7%)
Pulmonary embolism (grade 4, 6.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
AEs

AEs

AESignificanceDosePopulation
ALT increased grade 3, 20%
DLT
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
Hyperbilirubinemia grade 3, 20%
DLT
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
thrombocytopenia grade 3, 6.7%
DLT
250 mg 2 times / day multiple, oral
RP2D
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
Pulmonary embolism grade 4, 6.7%
DLT
250 mg 2 times / day multiple, oral
RP2D
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/17317835
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY111453
https://www.001chemical.com/chem/search?q=DY111453
1PlusChem LLC
1P007AI6
https://www.1pchem.com/search?query=1P007AI6
AK Scientific
2337AH
https://aksci.com/item_detail.php?cat=2337AH
AK Scientific
SYN1033
https://aksci.com/item_detail.php?cat=SYN1033
AK Scientific
X7480
https://aksci.com/item_detail.php?cat=X7480
Ambeed
A116887
http://www.ambeed.com/search/Search.html?keyword=A116887
Angene
AGN-PC-0RG9WW
http://www.angenechemical.com/productshow/AGN-PC-0RG9WW.html
ApexBio Technology
A2412
https://www.apexbt.com/catalogsearch/result/?q=A2412
AstaTech
C74959
http://astatechinc.com/CPSResult.php?CRNO=C74959
Axon MedChem
1537
https://www.axonmedchem.com/product/1537
BioSynth
J-501857
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/J-501857
BLD Pharm
BD630684
http://www.bldpharm.com/search/Search.html?keyword=BD630684
Capot Chemical
20545
https://www.capotchem.com/search.do?q=20545
Cayman Chemical
19172
http://www.caymanchem.com/app/template/Product.vm/catalog/19172
Chem Scene
CS-0262
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0262
ChemShuttle
109752
https://www.chemshuttle.com/catalogsearch/result/?q=109752
ChemShuttle
157335
https://www.chemshuttle.com/catalogsearch/result/?q=157335
Debye Scientific
DB-028138
https://www.debyesci.com/index.php?id=product&ext[cno]=DB-028138
eMolecules
275093523
https://orderbb.emolecules.com/search/#?query=275093523
eMolecules
31507573
https://orderbb.emolecules.com/search/#?query=31507573
eMolecules
44842435
https://orderbb.emolecules.com/search/#?query=44842435
eNovation Chemicals
D518750
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D518750&searchbtn.x=0&searchbtn.y=0
Excenen
EX-A2355
http://www.excenen.com/searchresultlist.php?id=EX-A2355
Hairui
HR113771
http://www.hairuichem.com/en/product/search.do?q=HR113771
KeyOrganics
AS-16200
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16200
Matrix Scientific
145202
http://www.matrixscientific.com/145202.html
mcule
MCULE-1816360303
https://mcule.com/MCULE-1816360303/
mcule
MCULE-2273855098
https://mcule.com/MCULE-2273855098/
MedChem Express
HY-14674
https://www.medchemexpress.com/search.html?q=HY-14674&ft=&fa=&fp=
Molcore
MC111453
http://www.molcore.com/CatMC111453.html
Molnova
M17499
https://www.molnova.com/en/serch-list.html?keywords=M17499
MolPort
MolPort-009-679-456
https://www.molport.com/shop/molecule-link/MolPort-009-679-456
MuseChem
I002211
https://www.musechem.com/product/I002211.html
MuseChem
I003412
https://www.musechem.com/product/I003412.html
ShangHai Biochempartner
BCP000144
http://www.biochempartner.com/search_BCP000144
ShangHai Biochempartner
BCP01844
http://www.biochempartner.com/search_BCP01844
TargetMol
T4014
https://www.targetmol.com/search?keyword=T4014
PubMed

PubMed

TitleDatePubMed
Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.
2008 Jun 26
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
2009 Apr
Patents

Patents

WO2004056830A1
2

Sample Use Guides

In Vivo Use Guide
In phase I-II clinical trials subjects received CP-724,714 as continuous oral daily doses on 21-day cycles for a predefined maximal duration of 17 cycles (51 weeks). There was no washout between cycles. The starting dose level was 250 mg QD. In subsequent dose cohorts, 250 mg BID, 400 mg BID, and 250 mg TID were evaluated. The maximal tolerated dose was identified as 250 mg TID.
Route of Administration: Oral
In Vitro Use Guide
CP-724714 inhibits erbB2 receptor autophosphorylation in NIH 3T3 cells expressing a chimeric receptor consisting of the EGFR extracellular domain and the erbB2 intracellular domain (IC50 15 ng/ml) and in vitro growth of SKBr3 cells (IC50 25 ng/ml).
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:43:09 GMT 2025
Edited
by admin
on Mon Mar 31 21:43:09 GMT 2025
Record UNII
I05QZ0S4V3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CP-724,714
Preferred Name English
CP-724714
Code English
ACETAMIDE, 2-METHOXY-N-(3-(4-((3-METHYL-4-((6-METHYL-3-PYRIDINYL)OXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2-PROPEN-1-YL)-
Systematic Name English
2-METHOXY-N-((2E)-3-(4-((3-METHYL-4-((6-METHYL-3-PYRIDINYL)OXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2-PROPEN-1-YL)ACETAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
Code System Code Type Description
PUBCHEM
9874913
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
ChEMBL
CHEMBL483321
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
DRUG BANK
DB12302
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
CAS
383432-38-0
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
EPA CompTox
DTXSID401026009
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
CHEBI
167658
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
CAS
537705-08-1
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
NON-SPECIFIC STEREOCHEMISTRY
FDA UNII
I05QZ0S4V3
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
SMS_ID
300000041486
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY
NCI_THESAURUS
C26648
Created by admin on Mon Mar 31 21:43:09 GMT 2025 , Edited by admin on Mon Mar 31 21:43:09 GMT 2025
PRIMARY NCIT
Related Record Type Details
Structure of CP-724714 SESQUISUCCINATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of CP-724714
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966